In the post-hoc analysis of the FDA end point, FDA response rates during the full 12-week interval were statistically superior for patients receiving 100 mg (28.0%; P = .002) and 200 mg (28.5%; P = .002) eluxadoline compared with placebo (13.8%) ( Table 3); patients receiving eluxadoline at 100 mg and 200 mg were more than twice Thiazovivin concentration as likely as placebo patients to be responders. A significantly higher pain response based on the WAP component of the FDA response definition was also seen for

the 100-mg eluxadoline group (55.2%; P = .045) compared with placebo (43.9%). Stool consistency response based on the stool consistency component of the FDA response definition was significantly higher for patients receiving 200 mg eluxadoline (36.9%; P = .013) compared with placebo (23.8%), with a similar trend observed for 100-mg eluxadoline patients (33.4%; P = 0.059). Post-hoc monthly analyses

during the intervals from weeks 1−4, 5−8, and 9−12 showed a consistently durable effect for overall FDA response, with rates for patients receiving 100 mg and 200 mg eluxadoline being statistically superior to placebo over the latter selleck products 2 intervals ( Table 3). Adverse event rates were similar across all groups and showed no obvious dose-dependent trend from 5 mg to 100 mg; however, patients in the 200-mg eluxadoline group reported higher rates of severe events, adverse events leading to discontinuation, and nonserious gastrointestinal and central nervous system events (Table 4). The most common gastrointestinal events reported were nausea, abdominal pain, vomiting, and constipation—the majority showing the highest rates in the 200-mg eluxadoline group. Although the rate of constipation was highest for the Phospholipase D1 100-mg eluxadoline group, none of the adverse events of constipation reported by these patients led to discontinuation

or was rated severe in intensity. A total of 5 adverse events of patient-reported constipation led to study drug discontinuation, 4 in the 200-mg eluxadoline group and 1 in the placebo group. Four patients discontinued from the study because of IVRS-confirmed constipation; 2 of these 4 patients also reported adverse events of constipation (which did not contribute to discontinuation) coincident to the IVRS data (one each in the 25-mg and 100-mg eluxadoline groups). No serious adverse events of constipation were reported. Three serious adverse events of pancreatitis were reported by patients during treatment with eluxadoline (2 at 200 mg and 1 at 25 mg). The 2 pancreatitis events at 200 mg occurred within the first 2 doses of study medication and the event at 25 mg occurred after 18 days of twice daily dosing; all resolved rapidly without sequelae. Among these 3 cases, one 200-mg event was confounded by a documented blood alcohol level of 76 mg/dL at the time of the event and a recent hospitalization for alcoholic pancreatitis 2 months before study entry.